KIRTI GANORKAR
Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma
Kirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, who remains Executive Chairman. This transition marks the culmination of Sun Pharma's succession plan, as Ganorkar steps into the role amidst a challenging global market.
Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the Board
Sun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi will continue as Executive Chairman, focusing on specialty portfolio and long-term strategy. Additionally, Richard Ascroft will succeed Abhay Gandhi as CEO – North America, reporting to Aalok Shanghvi, who takes on additional responsibility for the North America business.
Sun Pharma launches medication for Erosive Esophagitis
Sun Pharmaceutical Industries has launched Fexuprazan tablets (40 mg) in India, branded as Fexuclue, to treat Erosive Esophagitis of all grades. Developed in collaboration with Daewoong Pharmaceutical, the drug showed over 95% healing efficacy in a Phase 3 study. This new treatment aims to meet the significant unmet medical need for this condition.
Sun Pharma inks pact with Takeda to introduce gastrointestinal drug in India
Sun Pharmaceutical Industries announced a licensing deal with Takeda Pharmaceutical to market Vonoprazan, a novel gastrointestinal drug, in India. The agreement allows Sun Pharma to commercialize 10 mg and 20 mg tablets of Vonoprazan, an innovative treatment for acid peptic disorders, under a non-exclusive patent license.
Sun Pharma scouting for innovative therapies to boost India business
Approved by the Indian drug regulator in May 2023, sovateltide can be administered within 24 hours for the treatment of ischemic stroke, almost five times more than the narrow time window of 4-5 hours offered by current treatment options like tissue plasminogen activator (TPA) called thrombolytic drugs that dissolve the clots that cause strokes. An ischemic stroke is a medical emergency that occurs when blood supply to part of a brain is blocked or reduced.
Sun Pharma inks pact with Bayer to sell drug for chronic kidney disease
Sun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights to Sun Pharma to distribute Finerenone under the brand name Lyvelsa. Sun Pharma CEO emphasizes commitment to providing innovative medicines to Indian patients.
- Go To Page 1
Sun Pharma to market Zydus' novel anti-CKD drug desidustat in India
“The addition of RYTSTAT further strengthens our nephrology portfolio in India," said Kirti Ganorkar, CEO - India Business, Sun Pharma.
Sun Pharma unit inks licensing pact with US-based firm to introduce drug to treat stroke
"The Phase 3 clinical trial for Tyvalzi conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke," Sun Pharma India Business CEO Kirti Ganorkar said. Tyvalzi is a first-in-class innovative drug which can help improve the quality of life of stroke patients, he added.
Sun Pharma launches novel therapy for dry eye disease in India
DED is caused when the quantity or quality of tears fails to keep the surface of the eye properly lubricated, and associated with symptoms such as inflammation. Increased screen time and other lifestyle changes, is cited as one of the main reasons for DED.
Sun Pharma plans to focus on market share, sales in bid to outdo rivals
As part of the strategy to stay ahead of its rivals in the highly fragmented domestic formulation business, Sun Pharma has embarked on major salesforce expansion by adding over 1,000 people per year in the last two years (2021 & 2022). It has a field strength of around 12,000 people, the largest in India.
Sun Pharma to expand field force in India by 10 pc this fiscal
"The field force expansion done in FY21 has met with good success and considering the current market conditions, we will be undertaking a further expansion of about 10 per cent for our field force in FY23, driven by the twin objectives of brand focus and geographical expansion," Sun Pharmaceutical Industries CEO (India Business) Kirti Ganorkar said in an analyst call.
Sun Pharma to launch first-in-class oral lipid-lowering drug in India
The Mumbai-based drug major said one of its wholly-owned subsidiaries plans to launch a first-in-class oral drug, Bempedoic Acid, in India for reducing LDL cholesterol.
Sun Pharma enters licensing pact with Lundbeck to launch novel anti-depressant pill in India
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.
Sun Pharma gets DCGI nod to market molnupiravir for COVID-19 treatment
Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply a generic version of molnupiravir in over 100 low and middle-income countries (LMICs) including India.
Pharma, healthcare industry looks to sustain momentum in 2022
Listing out difficulties for the domestic pharma industry, Sun Pharma CEO (India Business) Kirti Ganorkar said that currency fluctuations, interest rate uncertainty and significant increase in raw material and transportation costs have been some of the major challenges.
Sun Pharma says gearing up to launch COVID drug molnupiravir
The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COVID-19 in adults. Earlier this year, Sun Pharma had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir in India and to over 100 low and middle-income countries (LMICs).
Sun Pharma, Ferring Pharmaceuticals ink pact to introduce obstetric drug in India
As per the agreement, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name Caritec. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the medicine in India, Sun Pharma said.
Sun Pharma to launch complete range of generic anti-epilepsy drug
The drug major introduced Brevipil (Brivaracetam) tablet in strengths of 25 mg/50 mg/75 mg/100 mg on February 21, while Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.
Aim to gain market share, protect supply chain, preserve cash amid COVID-19 uncertainties: Sun Pharma
"Our endeavour will be to gain market share in each of our business by doing better. Despite the near-term uncertainties related to COVID-19, we hope to be able to do better consistently," Sun Pharmaceutical Industries MD Dilip Shanghvi said in an analyst call.
Sun Pharma, US-based Rockwell Medical enter into licensing pact for Triferic in India
As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialisation partner for Triferic during the term of the agreement, subject to its approval in India.
Sun Pharma arm enters pact with China Medical System
China Medical System will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential, the company said in a statement.
Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drug
The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the contract is about $55.5 million.
Sun Pharma, NIV join hands to fight zika, chikungunya, dengue
Under the agreement, Sun Pharma will provide drug molecules to NIV for testing against zika, chikungunya and dengue in model systems, the company said in a statement.
Sun Pharma to acquire oncology product from Novartis for $175 mn
The agreement has been signed between subsidiaries of both the companies and will close following anti-trust clearance and further closing conditions, the Mumbai-based company said in a statement.
SPARC, Sun Pharma climb on licensing agreement
The deal will make the company eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XRTM, SPARC said.
ICGEB, Sun Pharma tie-up to develop novel dengue drug
ICGEB and Sun Pharma will develop the drug, known as Cipa, following a registration process that consists of trials and studies that meet both Indian and international regulatory standards.
Sun Pharma inks pact to develop nervous system drugs
The company will have commercial rights to this product globally. It will also fund all future studies to be conducted on the enzyme.
SPARC licenses Xelpros to Sun Pharma for US market
Sun Pharma Advanced Research Company (SPARC) has licensed out Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the US market.
Sun Pharma, Israel university ink pact to develop anti-cancer drugs
Sun Pharmaceutical Industries has inked a pact with Israel's Technion university to develop anti-cancer drugs.
Load More
